東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

PROTAC-mediated protein degradation ...

Nandave, Mukesh.

Linked to FindBook

Google Book

Amazon

博客來

PROTAC-mediated protein degradation = a paradigm shift in cancer therapeutics /

Record Type:	Electronic resources : Monograph/item
Title/Author:	PROTAC-mediated protein degradation/ edited by Mukesh Nandave, Priti Jain.
Reminder of title:	a paradigm shift in cancer therapeutics /
other author:	Nandave, Mukesh.
Published:	Singapore :Springer Nature Singapore : : 2024.,
Description:	xxii, 385 p. :ill. (some col.), digital ;24 cm.
[NT 15003449]:	1. Understanding the Ubiquitin Proteasome System - History and Revolution -- 2. PROTACs: Principles and Mechanisms -- 3. Structural Considerations and Chemistry of PROTAC -- 4. Advantages and Disadvantages of PROTACs -- 5. Novel Technologies in PROTAC Design -- 6. Future of trends in the design and development of PROTAC -- 7. Global Regulatory Requirements Applicable for PROTACs -- 8. Tissue-Specific Targeting Strategies with PROTAC Technology -- 9. Clinical Development OF PROTACs -- 10. Toxicological Aspects of PROTACs -- 11. PROTACs in the management of Prostate Cancer -- 12. Exploring the Role of PROTACs for the Treatment of Breast Cancer -- 13. Role of PROTACs in Hematological Malignancies -- 14. Artificial Intelligence and Machine Learning for Exploring PROTAC in Underutilized Cells -- 15. PROTACs in Treatment of Glioma -- 16. Proteolysis Targeting Chimera (PROTACs) an Attractive Technology in CVD Therapeutics: Opportunities and Challenges -- 17. Delivery systems - miniaturised PROTAC, Nano PROTAC, Aptamer-based RNA PROTAC.
Contained By:	Springer Nature eBook
Subject:	Cancer - Chemotherapy. -
Online resource:	https://doi.org/10.1007/978-981-97-5077-1
ISBN:	9789819750771

PROTAC-mediated protein degradation = a paradigm shift in cancer therapeutics /
PROTAC-mediated protein degradationa paradigm shift in cancer therapeutics /[electronic resource] :edited by Mukesh Nandave, Priti Jain. - Singapore :Springer Nature Singapore :2024. - xxii, 385 p. :ill. (some col.), digital ;24 cm.

1. Understanding the Ubiquitin Proteasome System - History and Revolution -- 2. PROTACs: Principles and Mechanisms -- 3. Structural Considerations and Chemistry of PROTAC -- 4. Advantages and Disadvantages of PROTACs -- 5. Novel Technologies in PROTAC Design -- 6. Future of trends in the design and development of PROTAC -- 7. Global Regulatory Requirements Applicable for PROTACs -- 8. Tissue-Specific Targeting Strategies with PROTAC Technology -- 9. Clinical Development OF PROTACs -- 10. Toxicological Aspects of PROTACs -- 11. PROTACs in the management of Prostate Cancer -- 12. Exploring the Role of PROTACs for the Treatment of Breast Cancer -- 13. Role of PROTACs in Hematological Malignancies -- 14. Artificial Intelligence and Machine Learning for Exploring PROTAC in Underutilized Cells -- 15. PROTACs in Treatment of Glioma -- 16. Proteolysis Targeting Chimera (PROTACs) an Attractive Technology in CVD Therapeutics: Opportunities and Challenges -- 17. Delivery systems - miniaturised PROTAC, Nano PROTAC, Aptamer-based RNA PROTAC.

This book is a comprehensive coverage of the ubiquitin-proteasome system and its involvement in cancer progression, and the application of PROTACs in different types of cancer treatment. The book discusses a unique perspective and comprehensive knowledge of the potential of PROTACs to transform cancer therapies. It provides an overview of the history, mechanisms, chemistry, design considerations, and different technologies involved in PROTACs. Additionally, it explains the ubiquitin-proteasome system, its impact on various diseases, and the principles and mechanisms of UPS. The book also describes the chemistry and design aspects of PROTACs and their role in various types of cancers. Finally, it covers the pharmaceutics aspect of formulation design, global requirements, and toxicological aspects of PROTACs. This book is targeted at cancer researchers, medical oncologists, bioinformatics, computational biologists, pharmacologists, medicinal chemists, formulation scientists, regulatory authorities, and policy makers.

ISBN: 9789819750771

Standard No.: 10.1007/978-981-97-5077-1doiSubjects--Topical Terms:

753516
Cancer
--Chemotherapy.

LC Class. No.: RC271.C5

Dewey Class. No.: 616.994061

PROTAC-mediated protein degradation = a paradigm shift in cancer therapeutics /
LDR:03130nmm a22003375a 4500 001 2388539
003 DE-He213
005 20240901130252.0
006 m d
007 cr nn 008maaau
008 250916s2024 si s 0 eng d
020 $a 9789819750771 $q (electronic bk.)
020 $a 9789819750764 $q (paper)
024 7 $a 10.1007/978-981-97-5077-1 $2 doi
035 $a 978-981-97-5077-1
040 $a GP $c GP
041 0 $a eng
050 4 $a RC271.C5
072 7 $a PSB $2 bicssc
072 7 $a SCI013040 $2 bisacsh
072 7 $a PNB $2 thema
082 0 4 $a 616.994061 $2 23
090 $a RC271.C5 $b P967 2024
245 0 0 $a PROTAC-mediated protein degradation $h [electronic resource] : $b a paradigm shift in cancer therapeutics / $c edited by Mukesh Nandave, Priti Jain.
260 $a Singapore : $b Springer Nature Singapore : $b Imprint: Springer, $c 2024.
300 $a xxii, 385 p. : $b ill. (some col.), digital ; $c 24 cm.
347 $a text file $b PDF $2 rda
505 0 $a 1. Understanding the Ubiquitin Proteasome System - History and Revolution -- 2. PROTACs: Principles and Mechanisms -- 3. Structural Considerations and Chemistry of PROTAC -- 4. Advantages and Disadvantages of PROTACs -- 5. Novel Technologies in PROTAC Design -- 6. Future of trends in the design and development of PROTAC -- 7. Global Regulatory Requirements Applicable for PROTACs -- 8. Tissue-Specific Targeting Strategies with PROTAC Technology -- 9. Clinical Development OF PROTACs -- 10. Toxicological Aspects of PROTACs -- 11. PROTACs in the management of Prostate Cancer -- 12. Exploring the Role of PROTACs for the Treatment of Breast Cancer -- 13. Role of PROTACs in Hematological Malignancies -- 14. Artificial Intelligence and Machine Learning for Exploring PROTAC in Underutilized Cells -- 15. PROTACs in Treatment of Glioma -- 16. Proteolysis Targeting Chimera (PROTACs) an Attractive Technology in CVD Therapeutics: Opportunities and Challenges -- 17. Delivery systems - miniaturised PROTAC, Nano PROTAC, Aptamer-based RNA PROTAC.
520 $a This book is a comprehensive coverage of the ubiquitin-proteasome system and its involvement in cancer progression, and the application of PROTACs in different types of cancer treatment. The book discusses a unique perspective and comprehensive knowledge of the potential of PROTACs to transform cancer therapies. It provides an overview of the history, mechanisms, chemistry, design considerations, and different technologies involved in PROTACs. Additionally, it explains the ubiquitin-proteasome system, its impact on various diseases, and the principles and mechanisms of UPS. The book also describes the chemistry and design aspects of PROTACs and their role in various types of cancers. Finally, it covers the pharmaceutics aspect of formulation design, global requirements, and toxicological aspects of PROTACs. This book is targeted at cancer researchers, medical oncologists, bioinformatics, computational biologists, pharmacologists, medicinal chemists, formulation scientists, regulatory authorities, and policy makers.
650 0 $a Cancer $x Chemotherapy. $3 753516
650 0 $a Ubiquitin. $3 2059079
650 1 4 $a Pharmaceutics. $3 3538434
650 2 4 $a Pharmacology. $3 634543
650 2 4 $a Drug Safety and Pharmacovigilance. $3 2108855
650 2 4 $a Oncology. $3 751006
650 2 4 $a Drug Delivery. $3 3531319
650 2 4 $a Pharmacy. $3 636101
700 1 $a Nandave, Mukesh. $3 3716232
700 1 $a Jain, Priti. $3 3753670
710 2 $a SpringerLink (Online service) $3 836513
773 0 $t Springer Nature eBook
856 4 0 $u https://doi.org/10.1007/978-981-97-5077-1
950 $a Medicine (SpringerNature-11650)